Download PDF
Planta Med 2020; 86(02): 104-112
DOI: 10.1055/a-1037-4081
Biological and Pharmacological Activity
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Preclinical Toxicology and Anticholangiocarcinoma Activity of Oral Formulation of Standardized Extract of Zingiber Officinale

Tullayakorn Plengsuriyakarn
1   Center of Excellence in Molecular Biology and Pharmacology of Malaria and Cholangiocarcinoma, Chulabhor International College of Medicine, Thammasat University, Pathum Thani, Thailand
2   Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand
,
Kesara Na-Bangchang
1   Center of Excellence in Molecular Biology and Pharmacology of Malaria and Cholangiocarcinoma, Chulabhor International College of Medicine, Thammasat University, Pathum Thani, Thailand
2   Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand
3   Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathum Thani, Thailand
› Author AffiliationsSupported by: National Reserach Council of Thailand 2016-201TU
Further Information

Publication History

received 31 July 2019
revised 22 October 2019

accepted 25 October 2019

Publication Date:
27 November 2019 (online)

    Permissions and Reprints

Abstract

Cholangiocarcinoma (CCA) remains a significant public health problem in Thailand. New effective and safe drugs are urgently needed. Zingiber officinale Roscoe (ZO) is a widely used medicinal plant for the treatment of several ailments, and the animal study suggests a potential anti-CCA activity. The present study aimed to develop the oral formulation of standardized extract of ZO and investigate toxicological profiles (acute, repeated dose, and chronic toxicity), including anti-CCA activity of the ZO formulation. The oral pharmaceutical formulation of the standardized ZO extract was successfully developed with an acceptable level of contamination and physicochemical and pharmaceutical properties. Acute, subacute, and chronic toxicity tests were conducted in healthy Sprague Dawley rats according to the OECD guidelines. The results showed no evidence of toxicity and death in the acute and subacute toxicity testing with the maximum tolerated dose (MTD) of 5000 and 2000 mg/kg body weight, respectively. Chronic toxicity revealed MTD and No-Observed-Adverse-Effect level (NOAEL) of 1000 mg/kg body weight. The anti-CCA activity was evaluated in CCA-xenografted mouse model. The formulated ZO powder was fed to animals daily for 30 days. Significant anti-CCA activity on tumor growth inhibition and prolongation of survival time were demonstrated at the high (2000 mg/kg body weight) and moderate (1000 mg/kg body weight) dose levels. Further investigation to elucidate molecular targets of action of ZO against CCA cells is encouraged.

Key words

Zingiber officinale - Zingiberaceae - cholangiocarcinoma - toxicity - xenografted model

Supporting Information

    Results of all formulation parameters and hematological and biochemical parameters of chronic toxicity study of the formulated ZO powder are available as Supporting Information.

  • Supporting Information
 

  • References

  • 1 Razumilava N, Gores G. Cholangiocarcinoma. The Lancet 2014; 383: 2168-2179
    CrossrefPubMedGoogle Scholar
  • 2 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 13: 261-280
    CrossrefPubMedGoogle Scholar
  • 3 Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Gastrointest Surg 2007; 31: 1258-1265
    PubMedGoogle Scholar
  • 4 Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H. British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61: 1657-1669
    CrossrefPubMedGoogle Scholar
  • 5 Ramirez-Merino N, Aix SP, Cortes-Funes H. Chemotherapy for cholangiocarcinoma: an update. World J Gastrointest Oncol 2013; 5: 171-176
    CrossrefPubMedGoogle Scholar
  • 6 Iwahashi S, Ishibashi H, Utsunomiya T, Morine Y, Ochir TL, Hanaoka J, Mori H, Ikemoto T, Imura S, Shimada M. Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. J Med Invest 2011; 58: 106-109
    CrossrefPubMedGoogle Scholar
  • 7 Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, Boudjema K, Fartoux L, Bouhier-Leporrier K, Jouve JL, Faroux R, Guerin-Meyer V, Kurtz JE, Assénat E, Seitz JF, Baumgaertner I, Tougeron D, de la Fouchardière C, Lombard-Bohas C, Boucher E, Stanbury T, Louvet C, Malka D, Phelip JM. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 2019; 37: 658-667
    PubMedGoogle Scholar
  • 8 Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, Kaneoka Y, Yamamoto M, Ambo Y, Shimizu Y, Ozawa F, Fukutomi A, Ando M, Nimura Y, Nagino M. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 2018; 105: 192-202
    CrossrefPubMedGoogle Scholar
  • 9 Duke JA, Bogenschutz-Godwin MJ, duCellier J, Duke PK. Handbook of Medicinal Herbs 2nd edition. Washington, D.C.: CRC Press LLC; 2002: 308-317
    Google Scholar
  • 10 Mascolo N, Jain R, Jain SC, Capasso F. Ethnopharmacologic investigation of ginger (Zingiber officinale). J Ethnopharmacol 1989; 27: 129-140
    CrossrefPubMedGoogle Scholar
  • 11 Podlogar JA, Verspohl EJ. Antiinflammatory effects of ginger and some of its components in human bronchial epithelial (BEAS-2B) cells. Phytother Res 2012; 26: 333-336
    PubMedGoogle Scholar
  • 12 Danwilai K, Konmun J, Sripanidkulchai B, Subongkot S. Antioxidant activity of ginger extract as a daily supplement in cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Manag Res 2017; 9: 11-18
    CrossrefPubMedGoogle Scholar
  • 13 Chen HC, Chang MD, Chang TJ. Antibacterial properties of some spice plants before and after heat treatment. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1985; 18: 190-195
    PubMedGoogle Scholar
  • 14 Martins LB, Rodrigues AMDS, Monteze NM, Tibaes JRB, Amaral MHA, Gomez RS, Teixeira AL, Ferreira AVM. Double-blind placebo-controlled randomized clinical trial of ginger (Zingiber officinale Rosc.) in the prophylactic treatment of migraine. Cephalalgia 2019; 39: 68-76
    CrossrefPubMedGoogle Scholar
  • 15 Ebrahimzadeh Attari V, Somi MH, Asghari Jafarabadi M, Ostadrahimi A, Moaddab SY, Lotfi N. The gastro-protective effect of ginger (Zingiber officinale Roscoe) in helicobacter pylori positive functional dyspepsia. Adv Pharm Bull 2019; 9: 321-324
    CrossrefPubMedGoogle Scholar
  • 16 Aryaeian N, Shahram F, Mahmoudi M, Tavakoli H, Yousefi B, Arablou T, Jafari Karegar S. The effect of ginger supplementation on some immunity and inflammation intermediate genes expression in patients with active rheumatoid arthritis. Gene 2019; 698: 179-185
    CrossrefPubMedGoogle Scholar
  • 17 Mahavorasirikul W, Viyanant V, Chaijaroenkul W, Itharat A, Na-Bangchang K. Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro . BMC Complement Altern Med 2010; 10: 55
    CrossrefPubMedGoogle Scholar
  • 18 Konmun J, Danwilai K, Ngamphaiboon N, Sripanidkulchai B, Sookprasert A, Subongkot S. A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy. Med Oncol 2017; 34: 69
    CrossrefPubMedGoogle Scholar
  • 19 Plengsuriyakarn T, Viyanant V, Eursitthichai V, Picha P, Kupradinant P, Itharat A, Na-Bangchang K. Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. BMC Complement Altern Med 2012; 12: 23
    PubMedGoogle Scholar
  • 20 Plengsuriyakarn T, Viyanant T, Eursiddhichai V, Tesana S, Chaijaroenkul W, Itharat A, Na-Bangchang K. Cytotoxicity, toxicity, and anticancer activity of Zingiber officinale Roscoe against cholangiocarcinoma. Asian Pac J Cancer Prev 2012; 13: 4597-4606
    CrossrefPubMedGoogle Scholar
  • 21 Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenum graecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1997; 56: 379-384
    CrossrefPubMedGoogle Scholar
  • 22 Langner E, Greifenberg S, Gruenwald J. Ginger: history and use. Adv Ther 1998; 15: 25-44
    PubMedGoogle Scholar
  • 23 Liang MH. From America: cookbook medicine or food for thought: practice guidelines development in USA. Ann Rheum Dis 1992; 51: 1257-1258
    CrossrefPubMedGoogle Scholar
  • 24 ElRokh el-SM Yassin NA, El-Shenawy SM, Ibrahim BM. Antihypercholesterolaemic effect of ginger rhizome (Zingiber officinale) in rats. Inflammopharmacology 2010; 18: 309-315
    CrossrefPubMedGoogle Scholar
  • 25 Ferri-Lagneau KF, Moshal KS, Grimes M, Zahora B, Lv L, Sang S, Leung T. Ginger stimulates hematopoiesis via Bmp pathway in zebrafish. PLoS One 2012; 7: e39327
    CrossrefPubMedGoogle Scholar
  • 26 Khosravani M, Azarbayjani MA, Abolmaesoomi M, Yusof A, Zainal AN, Rahimi E, Feizolahi F, Akbari M, Seyedjalali S, Dehghan F. Ginger extract and aerobic training reduces lipid profile in high-fat fed diet rats. Eur Rev Med Pharmacol Sci 2016; 20: 1617-1622
    PubMedGoogle Scholar
  • 27 Zhao XX, Lu M, Zhu X, Gao P, Li YL, Wang XM, Ma DY, Guo XH, Tong BY, Yang XL, Du WW, Zhou SF, Liu HM, Ran PF, Lü XR. Multi-central clinical evaluation of ginger-partitioned moxibustion for treatment of leukopenia induced by chemotherapy. Zhongguo Zhen Jiu 2007; 27: 715-720
    PubMedGoogle Scholar
  • 28 Shahdadi H, Nasiri AA, Sepehri Z, Poodineh Moghadam M, Kiani Z. The effect of ginger powder on blood lipid profile, fasting blood glucose, and blood pressure in hyperlipidemic men: a clinical trial study. ZBMUJ 2014; 6: 78-87
    PubMedGoogle Scholar
  • 29 Attari VE, Mahluji S, Jafarabadi MA, Ostadrahimi A. Effects of supplementation with ginger (Zingiber officinale Roscoe) on serum glucose, lipid profile and oxidative stress in obese women: a randomized, placebo-controlled clinical trial. Pharm Sci 2015; 21: 184-191
    CrossrefPubMedGoogle Scholar
  • 30 Rong X, Peng G, Suzuki T, Yang Q, Yamahara J, Li Y. A 35-day gavage safety assessment of ginger in rats. Regul Toxicol Pharmacol 2009; 54: 118-123
    CrossrefPubMedGoogle Scholar
  • 31 Mega TP, Kocyigit SS, Kilinc O, Orun O. Biological effects of whole Z. officinale extract on chronic myeloid leukemia cell line K562. Gene 2019; 692: 217-222
    CrossrefPubMedGoogle Scholar
  • 32 Akimoto M, Iizuka M, Kanematsu R, Yoshida M, Takenaga K. Anticancer effect of ginger extract against pancreatic cancer cells mainly through reactive oxygen species-mediated autotic cell death. PLoS One 2015; 10: e0126605
    CrossrefPubMedGoogle Scholar
  • 33 Pashaei-Asl R, Pashaei-Asl F, Mostafa Gharabaghi P, Khodadadi K, Ebrahimi M, Ebrahimie E, Pashaiasl M. The inhibitory effect of ginger extract on ovarian cancer cell line; application of systems biology. Adv Pharm Bull 2017; 7: 241-249
    CrossrefPubMedGoogle Scholar
  • 34 Tuntiwechapikul W, Taka T, Songsomboon C, Kaewtunjai N, Imsumran A, Makonkawkeyoon L, Pompimon W, Lee TR. Ginger extract inhibits human telomerase reverse transcriptase and c-Myc expression in A549 lung cancer cells. J Med Food 2010; 13: 1347-1354
    CrossrefPubMedGoogle Scholar
  • 35 Plengsuriyakarn T, Viyanant V, Eursitthichai V, Itharat A, Na-Bangchang K. In vitro investigations on the potential roles of Thai medicinal plants in treatment of cholangiocarcinoma. Int J Pharm Pharmacol 2012; 2: 1-12
    PubMedGoogle Scholar
  • 36 Dongare S, Gupta SK, Mathur R, Saxena R, Mathur S, Agarwal R. Zingiber officinale attenuates retinal microvascular changes in diabetic rats via anti-inflammatory and antiangiogenic mechanisms. Mol Vis 2016; 22: 599-609
    PubMedGoogle Scholar
  • 37 Zhong W, Yang W, Qin Y, Gu W, Xue Y, Tang Y, Xu H, Wang H, Zhang C, Wang C, Sun B, Liu Y, Liu H, Zhou H, Chen S, Sun T, Yang C. 6-Gingerol stabilized the p-VEGFR2/VE-cadherin/β-catenin/actin complex promotes microvessel normalization and suppresses tumor progression. J Exp Clin Cancer Res 2019; 38: 285
    CrossrefPubMedGoogle Scholar
  • 38 Lee HS, Seo EY, Kang NE, Kim WK. [6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells. J Nutr Biochem 2008; 19: 313-319
    CrossrefPubMedGoogle Scholar
  • 39 Thai Herbal Pharmacopoeia 2017. Available at: https://bdn.go.th/attachment/services/download.php?WP=q3MZp21CM5O0hJatrTgjWz03qmAZZz1CM5O0hJatrTDo7o3Q Accessed December 6, 2018
    PubMedGoogle Scholar
  • 40 The United States Pharmacopoeia 41 – National Formulary 36:. United States Pharmacopeial Convention. Available at: http://www.usp.org/ Accessed May 1, 2018
    PubMedGoogle Scholar
  • 41 European Medicines Agency. Guideline on quality of herbal medicinal products/traditional herbal medicinal products UK, European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-herbal-medicinal-products-traditional-herbal-medicinal-products_en.pdf Accessed March 31, 2011
    PubMedGoogle Scholar
  • 42 British Pharmacopoeia UK, 2018. Available at: https://www.pharmacopoeia.com/downloads/bp/2018/ Accessed January 1, 2018
    PubMedGoogle Scholar
  • 43 Hunt DG, Chandler C, Ulrich DA, Poska R, Montero A. USP controlled room temperature range expansion. Pharmacopeial Forum 2013; 39: 1-5
    PubMedGoogle Scholar
  • 44 OECD. OECD guidelines for the testing of chemicals, acute oral toxicity-fixed dose procedure (OECD 420). Available at: https://www.oecd-ilibrary.org/docserver/9789264070943-en.pdf?expires=1562950830&id=id&accname=guest&checksum=93E95262DCB300DD7D43C0EB6138D9C4 Accessed December 17, 2001
    PubMedGoogle Scholar
  • 45 OECD. OECD Guidelines for the Testing of Chemicals, Repeated Dose 28-Day Oral Toxicity Study in Rodents (OECD 407). Available at: https://www.oecd-ilibrary.org/docserver/9789264070684-en.pdf?expires=1562951228&id=id&%20accname=guest&checksum=AA8A56414FCD056017B8167F363218FF Accessed October 3, 2008
    PubMedGoogle Scholar
  • 46 OECD. OECD Guidelines for the Testing of Chemicals, Chronic Toxicity Studies (OECD 452). Available at https://www.oecd-ilibrary.org/docserver/9789264071209-en.pdf?expires=1562951326&id=id&accname=guest&checksum=BB25D738DACFA8501574F27124D63D1C 2018. Accessed June 25, 2018
    Google Scholar